Study S003348

A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004

ClinicalTrials.gov record

Registration

Registration: NCT06813781
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 33
Start: 2024-12-19
Primary completion: 2025-10-02
Lead sponsor: AstraZeneca
Conditions: Hepatic Impairment
Interventions: DRUG:AZD5004
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

AUCinf [Day 1 to Day 6]
AUClast [Day 1 to Day 6]
Cmax [Day 1 to Day 6]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.